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Abstract 
 
The objective of the 8th MDG is to promote global partnership between Multinational 
Enterprises (MNEs) and domestic firms with or without intervention of a subsidiary. 
Addressing the particular needs of developing countries, such as capability enhancement or 
poverty reduction by managers of MNEs in a global setting becomes very complex. 
Investments by multi national enterprises (MNEs) in developing countries are driven by 
return on investments they provide and linkages they create for developing competence 
required for MNEs to survive successfully in a competitive market Need for an inclusive, 
accountable and effective cooperation for development of least developed countries urges 
academics to develop business models for managers of MNEs that can guide their thoughts 
and actions towards social development while holding on to the business targets.  
 
Keywords: MNE, Branding, Returns on Investments, Social Development, Capability 
Enhancement and Poverty Reduction. 
 
 
Introduction 
The strategy used by a pharmaceutical MNE to identify its route into the drug market 
depends upon the health support available to patients and the dynamics of the market. 
Countries without a health support system such as that available in developed countries, are 
generally developing countries (Arnoldi et al., 2014).  MNEs in developing markets 
strategize their business operations based upon the trade-off opportunity assessed by them in 
the target market and the risk involved in entering a developing market (Jones, 2010). 
Linkages enable managers in home countries to understand the trade-offs they can make in 
the developing markets.  The linkages build capability of MNEs to penetrate and improve 
performance in the foreign market.  Thereafter, spill over effects of all these linkages are both 
direct and indirect for the MNE, the local market, local firms and consumers.  Although 
influence of spillovers is studied extensively, knowledge about ability of expansion of MNE 
operations through local linkages in a developing country to meet social challenges is now 
known.  Help from institutions provided to MNEs at the macro level as support for capacity 
building initiatives, or for removing trade-restrictive measures, or by eliminating export 
subsidies and trade-distorting support given to agricultural exports becomes very important 
for social development in developing markets. Although bilateral and multilateral agreements 
increase the management burden on recipient countries on the one hand and raise need for 
coordination on issues for the donors and lenders on the other.  Simultaneously, cost benefit 
analyses of entering developing markets to either improve production capacity or to conduct 
research and development activities at low cost or to obtain new technology or to increase 
profit from sales, aims to improve the positioning of the MNE in the global market.   
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The global market for pharmaceutical MNEs manufacturing medicines as assessed by 
PricewaterhouseCoopers (PwC) will be 1.5 trillion USD in the year 2020, and according to a 
report by BCC Research, the size of the segment consuming generic medicines will 
experience the highest growth rate.  These forecasts by PwC are based on recognition of an 
aging population and growing life expectancy in countries like India, China, Brazil, Russia 
and Mexico.  As indicated by the MDG task force, PwC and BCC research: access to 
essential and affordable medicines is a critical MDG to be achieved through global 
partnership because if medicines are expensive, people will have to make catastrophic 
payments in order to achieve a higher status of health. FDIs by pharmaceutical MNEs in 
developing countries are guided by international trade policy monitored by the World Trade 
Organisation (WTO) and World Health Organisation (WHO) monitors global health policy.  
While WTO aims to establish free trade and commercial practices across the globe, the goal 
of WHO is to facilitate timely diagnosis and access to medicines for all.  WTO encourages 
the entry of R&D based pharmaceutical MNEs from developed markets into developing 
markets and WHO promotes the demonstration of good citizenship by these MNEs through 
participation in making essential medicines affordable and accessible (Flynn, 2014).  
Integration of objectives of MNEs, WTO and WHO when referring to access to medicines 
reflects on the role of national governments and public institutions operating in countries 
being targeted by them.  Therefore, strategies that can be adopted by MNEs from developed 
countries to provide access to medicines in developing countries, merit investigation.   
 
Despite an increase in international trade in medicines by MNEs and efforts of the World 
Health Organisation (WHO) to safeguard the health of people in its member states, one-third 
of the population in developing countries still does not have access to affordable essential 
medicines.  A report published by the United Nations, New York, in 2015 on progress of the 
Millennium Development Goals in relation to developing countries suggests that availability 
of medicines through private facilities in these countries is higher in comparison to public 
health facilities.  This report also reflects on the lack of availability of initial diagnostic test 
facilities required for prescribing the right medicines by medical practitioners.  Using survey 
data collected from households of sub-Saharan Africa during 2012 to 2014, a WHO report 
suggests that only 20% of children suffering from fever received a diagnostic test.  Influence 
of lack of such medical interventions combined with non-availability of medicines pushes 
WHO to engage the international private sector and promote public-private partnerships at 
the national level. Inflow of FDI by MNEs can be determined by the policies of government 
in the host country (Dunning, 2014). Policies formulated by the government in Ghana allow 
pharmaceutical MNEs and their subsidiaries to benefit from incentives like tax exemption for 
the first ten years of operation, tax rebates and Free Zones Enclave (Summit, 2014). Other 
incentives including a zero corporation tax for setting up manufacturing plants in identified 
locations reduce the overall expense incurred for production, thereby giving MNEs an 
opportunity to reduce the price of medicines in Ghana (Summit, 2014).  The government in 
Brazil also offers exemption from tax for up to three years but requires companies to invest a 
percentage of their profits in research and development through institutions or universities, 
and the government of India provides an environment that offers growth through research and 
development to MNEs (Flynn, 2014).   
Martens et al. (2011) conceptualized a framework linking globalization and the health related 
requirements of future populations.  With population health being the central focus, the 
framework of Martens et al. (2011) explains the formative nature of various contextual, distal 
and proximal determinants to influence population health.  The study presents five features 
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that influence global dynamics, i.e. 1) global governance structures, 2) global markets, 3) 
global mobility, 4) cross-cultural interactions and 5) global environment.  Investigation 
conducted by Martens et al. (2011) highlights the ability of four of these features to drive four 
distal determinants - health policy, economic development, knowledge and social 
interactions, and ecosystem goods and services.  Next, the model underlines how population 
health during globalization depends upon dynamic interaction between various factors such 
as health related policies that influence health services and the effect of social environment 
on lifestyle. For example a high or low fat diet depends upon the knowledge gained and 
social interactions between actors.  This research reflects a need for MNEs to step aside from 
a commercial agenda as a usual business attitude and aim to provide sector-based solutions 
with short-term remedies.  Considering the complexity of multi-dimensional and multi-level 
causation of population health, Martens et al. (2011) highlight the need for both state and 
non-state actors to actively feel responsible for participation in the global health agenda.  
Authors have explained that the last MDG, i.e. “global partnership for development”, is 
feasible and the goal can be achieved with the engagement of the private sector at the global 
level, i.e. MNEs.   
A study conducted by Jones (2010) reviewed the opportunities and risks faced by 
multinational strategies in developing countries during three different eras of globalization, 
namely 1) the global economy from 1850-1929, 2) the de-globalization period from 1929-
1978 and 3) the second global economy from 1978 onwards. He explained that the trade-off 
is determined by MNEs based on three very different but related factors, i.e. policies of both 
the host country and the home country, the target market and resources available in the host 
country and the competitiveness of local firms in the host country.  As discussed by Jones 
(2010), the performance of an MNE in a developing country is an outcome of its strategies 
that are based on its internal capabilities that enable it to respond to opportunities and threats 
existing in the host country.  This research reviewed investments made by MNEs in 
developing countries from the year 1914 till 2007.  The findings reveal that MNE 
investments in developing countries during the year 2007 were less than 50% of the value of 
investments in the year 1914.  The author also reveals that throughout the three eras, social 
and infrastructural development of target markets has consistently been an integral part of the 
FDI strategy of MNEs. The WHO framework for providing access to medicines recommends 
the incorporation of four main factors in their strategies: 1) rational selection and use of 
medicines, 2) affordable prices, 3) sustainable financing and 4) reliable health and supply 
systems.  The following sections present a discussion on the incorporation of these aspects 
into strategies adopted by pharmaceutical MNEs for developing countries. 
 
MNEs in a Global World 
Globalization facilitates efficient sourcing of raw material and production, as well as 
providing opportunities of huge sales (Porter, 2000).  Higher sales have a ripple effect on cost 
of production and raw materials, making businesses more profitable for MNEs but they pose 
risks like counterfeiting (Chandler, 1959). Therefore, MNEs use patents to protect their 
innovations, brands to introduce their innovations and trademarks to protect their brands 
(Allred and Park, 2007).  The World Trade Organisation (WTO) made an attempt to protect 
local industry in developing countries from price-based strategies adopted by MNEs, by 
obliging them to reduce their prices and create competition for the local industry (Ford et al., 
2007).  Simultaneously, to safeguard the interest of patients with low ability to pay, World 
Health Organisation (WHO) recommended the engagement of local governments for 
improving conditions related to access to essential medicines at affordable prices (Ford et al., 
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2007).  These recommendations encouraged governments in developing countries to build or 
improve infrastructure at public health centres for the provision of medicine manufactured 
either locally or by MNEs (Sallis et al., 1998).  Availability of infrastructure as resources in a 
market with a high potential for business encourages MNEs to consider creating a base for 
their company in the market by making financial investments (Porter, 2000).  A country with 
the necessary infrastructure is expected to attract higher FDI (Porter, 2000). Linkages created 
in the host country by a pharmaceutical MNE through a local subsidiary can have both direct 
and indirect influence on local firms, local population and the MNE (Figure 2).  Therefore, 
the focus of this study is on benefits received by local firms from their engagement with 
MNEs in the form of capability enhancement, local population gains from poverty reduction 
due to improved health conditions and facilities.  A reward for the MNE in such a setting is 
conceptualized to include increase in brand value and brand reputation. 
 
FDI by MNEs  
Demonstrating direct and indirect effects of FDI by MNEs, governments permit FDI in both 
green-field as well as brown-field projects. But, a reform is required to facilitate healthcare 
and access to medicines for poor patients in the developing world who depend mainly on 
generics and cannot afford to pay for branded medicines.  Efforts of voluntary organisations 
such as Global Alliance for Vaccine and Immunization (GAVI) and UN Compact are also not 
able to ensure engagement of pharmaceutical MNEs in development through sustainable 
access to essential medicines. In Brazil, MNEs create links with local firms and appoint a 
custodian institution registered with the Brazilian Securities Commission (Torres Filho et al., 
2014).  The linkages developed enable MNEs to optimise investments made and make use of 
the benefits provided like tax exemption by host countries (Flynn, 2014).  In order to set up 
linkages in host countries, MNEs adopt various routes like a joint venture or an export 
channel or a subsidiary or a distribution channel (Dunning, 1999).  State governments in 
Brazil compete with each other to host MNEs by autonomously offering benefits like support 
in the creation of linkages, while central government regulates the repatriation of MNE profit 
(Sundaram, 2014). Anecdotes indicate that governments in developing countries support the 
health sector with sustainable financing using a percentage of the country’s GDP and by 
controlling prices of selected medicines identified to be essential by experts. These controls 
restrict pharmaceutical MNEs from putting a mark-up and charging a premium price, thereby 
restricting the availability of their products in the developing country.  
Marketing Strategies of MNEs  
The market for medicines or drugs can be divided into 1) prescribed patented or non-patented 
drugs and 2) non-prescribed over the counter drugs (Paris and Docteur, 2007).  The non-
patented and over the counter drug market is being served with branded generics or 
unbranded generics in both the developed and developing countries by local manufacturers or 
MNEs (Sundaram, 2014). The efficiency of state-provided health support services in 
developed countries encourages drug manufacturing MNEs to supply generic medicines at 
low cost. However the business dynamics and governance prevailing in the markets of 
developing countries makes MNEs push branded generics as high quality products 
(Ravindran, 2014).  Branded generics allow MNEs to charge a high price and increase their 
profits from people whose paying capacity is much less (Rosenthal et al., 2003).  A review by 
Ailawadi et al. (2001) of value-based pricing strategy adopted by Procter and Gamble 
highlighted that the price paid by consumers is negatively associated with market share, and 
price cuts allow stronger market penetration because steep price cuts motivate buyers to focus 
on promotion instead of on brand, and special promotions can influence consumer 
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preferences at the point of purchase. The other alternative suggested by scholars such as 
Raulinajtys-Grzybek (2014) is, cost-based pricing calculated on the basis of costs incurred by 
the manufacturer to produce the product.  
The cost-based pricing methodology uses costs to identify a cost range that provides 
minimum and maximum prices for a specific product or service.  As indicated by previous 
researchers, if the market conditions are such that the going competitive price is very low, the 
company may price its products at the minimum possible amount (Hill et al. 2014).  But, 
adopting this strategy for pricing is difficult in developing countries due to asymmetry in 
information about either the market or the patient in developing countries (Hill et al. 2014).  
Therefore, the demand for medicines and healthcare for developing countries is identified by 
the assumptions of physicians or pharmacists (Arnoldi et al., 2014). Thus the concepts of 
brand awareness, brand credibility, association and reputation for pharmaceutical MNEs are 
all focused on the relationships of manufacturers with chemists and doctors (Ahmad and 
Sattar, 2014). Representatives appointed by manufacturers also find it difficult to acquire 
complete medical information. Hence, different types of incentives are passed on to actors 
involved in promoting the branded generics, using various unethical trade practices (Rose-
Ackerman and Tan, 2014). As generics are often thought to be sub-standard and the choice of 
medicine does not lie with consumers, patients end up paying higher amounts for branded 
medicines that could have been easily purchased at a much lower price if generics were 
bought (Sundaram, 2014). Adoption of market based pricing policy as an effort to reduce the 
cost of essential drugs, by making them affordable for national governments, and by 
launching patent-protected drugs at a very low price in comparison to the global price, has 
generally not yielded improvement in issues related to access to medicines.   
	
Acquisition	for	Control	
Evidence of acquisition as a strategy adopted by firms wanting to expand can be found in the 
pharmaceutical industry with cases such as Ranbaxy, an Indian company that took over 30% 
stakes in Vorin Labs to benefit from its strong hold in the market because of products such as 
Ciprofloxacin, Enrofloxacin and Indinavir. Acquisition via FDI allows MNEs to get 
immediate access to local linkages through a fully operational business (Meyer, 1995). MNEs 
operating across multiple countries reduce their transaction costs by expanding their 
production capacity through acquisition of local manufacturers to benefit from economies of 
scale (Dunning, 2014).  These MNEs also increase the size of their product portfolio to 
address needs of different categories of customers at every point of purchase to benefit from 
economies of scope (Buckley and Ghauri, 2004).  Efficient production and marketing 
capabilities enable MNEs to exploit complementarity between their product segments and to 
establish their dominance in the global market as market leaders by serving customers in 
different countries (Dunning, 2014). Developing production capabilities requires vertical 
integration but improving marketing capabilities requires horizontal integration (Dunning, 
1999).  Vertical integration improves business efficiency and acquiring competing businesses 
as a horizontal integration strategy enables firms to increase their market share and grow their 
business in the global market.  
Technological	Efficiency	
Dahan et al. (2010) explored new business models for developing markets and recommended 
that building a reliable medicine supply system in a developing country required engagement 
of the private sector.  Certain state governments in developing countries such as India have 
made attempts to develop their own mechanisms to provide access to medicines, but they 
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have failed owing to lack of information required to efficiently manage a supply chain. 
Another issue that led to the failure of the efforts of state governments in India was the 
duplication of schemes run by the state, the centre, the hospitals etc. While there are many 
examples of such failures, the state of Tamil Nadu in India has created an exceptional 
medicine procurement and distribution system, which other states are trying to replicate. The 
success of the private sector and government of Tamil Nadu in efficiently managing supply 
of medicines can be credited to the information support they received from the use of 
technology. The state government of Tamil Nadu and the public sector are monitoring the 
inventory and delivery of medicines through public health facilities using technology based 
state of the art enterprise resource planning systems that facilitate ordering and delivery of 
medicines transparently using first in, first out rule with minimum stock levels.  A study 
conducted by Meyer (1995) investigated the role of issues such as energy, natural resources, 
pollution and waste in building economic competency to explain how corporations can gain 
competitive advantage by managing variables related to ecological health. The findings of the 
research conducted by Meyer (1995) reflected on technological orientation as a tool for 
competitive advantage and explained how organisational processes, when managed using 
technology, can enhance the competitiveness of a firm.  A management strategy that 
incorporates use of technology for efficiently providing access to medicines will therefore, 
improve the performance of MNE in the target market. 
Greenfield	Investments			
MNEs’ contribution to the development of the local economy in the form of efforts related to 
improvement in health facilities, job creation, skill development, infrastructure to promote 
sanitation or education, promotion of renewable energies, can all be percieved as green-field 
investments (Agwu, 2014).  Studies by scholars like Rush et al. (2014) also discuss outcomes 
of MNE initiatives to support local firms whose resources enable the MNE to build local 
capabilities, absorptive capacity and market positioning through production and employment 
creation, and these need to be considered. Developing market administrators classify these 
initiatives into Greenfield or Brownfield investments and explain existing trends as being 
based on the focus of MNEs on driving shareholder value.  A report on FDI in the 
pharmaceutical sector by the Rajya Sabha Secretariat in India shows that out of 67 FDI 
investments up to September 2011, only one was a Greenfield project, while all the remaining 
FDI has come in brownfield projects.  
The selection of Greenfield i.e. initiating a new startup versus Brownfield i.e. acquisitions as 
an investment strategy by MNEs is driven by competition intensity, experience of operating 
in a foreign country and technological efficiency (Meyer and Estrin, 2001). High costs 
involved in production and process management of drug manufacturing have encouraged 
various pharmaceutical companies from developed countries to outsource their 
manufacturing processes to developing countries (Mascarenhas et al.. 1998).  Unfortunately, 
the outsourcing of these activities by MNEs from developing countries has been generally 
restricted to areas where resources are available, and has not contributed to building of 
infrastructure in areas that lack resources and facilities (Agwu, 2014).  Alternate investments 
of MNEs reviewed by Dunning and Lundan (2008) also have been towards development of a 
distribution network useful to MNEs for marketing and sales of their products in areas with 
high sales potential.  These studies emphasize that managers of MNEs consider investments 
in favour of strengthening their supply network to compete and survive in the market instead 
of promoting distribution into the areas that need development and lack infrastructure 
required to provide access to medicines (Labonte et al., 2005). Non-availability of a medicine 
retailer or a pharmacy or a hospital in a remote area with very low business potential but high 
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poverty directly highlights the problems related to access to medicines for the poor, making 
healthcare very expensive for them (Labonte et al., 2005). 
The autonomy enjoyed by subsidiaries of MNEs allows them to create linkages for efficient 
functioning of regular business activities like marketing, purchasing and recruiting (Ho, 
1998). The spill over effect of subsidiary activities that enables MNEs to identify 
opportunities of Greenfield investments in rural underdeveloped areas of developing 
countries can improve access to medicines and simultaneously increase share of the market 
for the MNE (Meyer, 1995).  An investigation of inward FDI on labour markets of 
developing countries by comparing the differences between productivity of local and foreign 
firms in host countries was carried out by Agwu (2014).  Based on the findings that the 
overall influence of increase in productivity is ultimately translated into regional 
development and job creation, Agwu (2014) recommended that Greenfield investments 
instead of brownfield investments would improve productivity, and thereafter, the 
competitiveness of the MNE in the host country. 
 
Innovation		
High costs and the risk involved in production and consumption of medicines pushes MNEs 
to outsource their research, development and production to developing countries (Buckley 
and Ghauri, 2004).  Developed countries are able to provide skilled staff and infrastructure 
with the production specific assets required to innovate, apart from maintaining and 
monitoring high quality standards of procedures and operations throughout the production 
and delivery process (Dunning, 1999).  Efforts related to research and development of 
pharmaceutical MNEs for innovation conducted in the developing countries have been 
restricted to process chemistry and reverse engineering capabilities, and have negligibly 
served the needs of the target market (Liu and Buck, 2007).  Another feature noticed in FDI 
inflow for R&D in developing countries has been that of 'out licensing', where the company 
in the host country leads in the pre-clinical stage and the MNE will possess the right to 
market, if drug clears all the required tests (Chien, 2003). The companies conducting research 
for pharmaceutical MNEs in developing countries are paid for passing each stage of clinical 
trials and compound approval.  Another issue noticed regarding R&D is the increasing 
collaboration between MNEs and local firms for unethical clinical trials of patients in phase 
III (Submitter et al., 2011).  Research on clinical trials conducted by Submitter et al. (2011) 
highlighted unethical practices of using a vulnerable non-traditional trial population in poor 
regions of developing countries by contract research organisations without giving them 
access to the innovation resulting from the research and development. 
Branding		
Perceptions of actors in the pharmaceutical industry are also affected by the marketing 
activities but, unlike other industries, pharmaceutical industry regulations require companies 
to receive legal authorization for marketing their drugs (Fingstein, 1996).  Parameters 
prescribed by WHO regarding qualification of drugs for marketing authorization entail the 
engagement of local governments for registering and publishing names of drugs registered, 
using their international non-proprietary names with or without their brand name. The 
acquisition of non-patented branded products enables MNEs to rapidly gain a share of the 
domestic market. Volumetric sale of branded products results in higher profits and 
availability of a marketing budget (Kim and Chung, 1997).  A brand enables MNEs to sustain 
their market share by efficiently marketing and communicating about their products in order 
to build awareness among naïve consumers (Ghauri and Usunier, 2003).  Consumers perceive 
the knowledge provided about the products and hazards of overconsumption or non-
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consumption through brand communications as brand value, and this moderates brand 
credibility in remote locations (Shaw et al., 2006).  Restrictions imposed on the marketing of 
drugs encourage pharmaceutical MNEs to use their company name as a corporate brand that 
can strengthen their market penetration capability (Dunning, 1999).  While MNEs acquire a 
business due to their interest in originator drugs, they use patents as a main strategy to curb 
competition (Ghauri and Usunier, 2003).  Other strategies used to address competition at the 
micro level are celebrity endorsements and expert advice as marketing techniques to attract 
customers and to persuade them in a competitive market (Ang et al., 2000).  Developing a 
capability to drive consumer behaviour requires pharmaceutical MNEs offering therapeutic 
drugs to create recognition amongst the consumer segment (Ailawadi et al., 2001).  Use of a 
brand enables an MNE to reflect on its philosophies, such as reciprocity and sensitivity to 
stakeholder needs, and build its credibility across geographical boundaries (Shaw et al., 
2006). Branding facilitates utilization of marketing techniques and tools across all consumer 
and business-to-business segments, making creation of linkages easy for MNEs (Ghauri and 
Usunier, 2003). 
Quality	Assurance	at	POP	
The medicines supplied at public health centres are generic medicines procured by the state 
government through a tendering or bidding process that requires medicines to qualify on 
prescribed quality and financial parameters (Chaudhury et al., 2005). As MNEs’ prices 
include high mark-ups for marketing and logistics cost, they fail to match the prices offered 
by manufacturers offering products without labels, thereby getting disqualified from the bid 
(Ghauri and Usunier, 2003).  Medicines offered by manufacturers without any label lack 
recognition by buyers about the quality of product and high standards of procedures adopted 
during production (Chaudhury et al., 2005).  Hence, generic medicines fail to assure buyers 
about quality of the product at the point of purchase (Hurwitz and Caves, 1988).  Therefore, 
the purchasing behaviour of patients while buying medicines at pharmacy stores or hospitals 
is driven by MNEs offering branded generics that are bioequivalent or off-patent products 
sold using a brand name.  The quality of drug depends on the active pharmaceutical 
ingredient (API);the bulk drugs for both the generic and branded generic markets are sourced 
from small-scale industry (Rai, 2008).  But, the supply chain expertise of MNEs and lack of 
trust on generics and non-availability of generics all influence the purchasing behaviour of 
customers and hinders the fulfilment of demand for generic medicines in the remote areas of 
developing countries (Hurwitz and Caves, 1988). Branded generics are promoted as reliable 
medicines to retailers, pharmacists and to doctors by MNEs along with high sales incentives 
(Rosenthal et al., 2003).  Promotion of branded generics by retailers and doctors creates a 
perception of low quality regarding generic medicines (Hurwitz and Caves, 1988). A study 
conducted by Ahearne et al. (2007) explains the importance of perceptions of quality when 
shared by promoters or sellers, i.e. doctors and retailers in the case of medicines, while 
buyers at the point of purchase can have an indirect effect on the performance of the firm 
(Ahearne et al. 2007).   
Transparency	in	Operations	
The agreement on Trade-Related aspects of Intellectual Property Rights (TRIPs) agreement 
provides flexibility to local governments for application of non-voluntary authorization of use 
of patents as compulsory licenses in conditions related to public health, i.e. for diseases like 
HIV/AIDS (Rai, 2008).  However, the international business environment today is 
apprehensive about the lack of transparency in the practices of MNEs in areas such as 
revealing the cost of a patented drug or justification of holding on to patents even after the 
expiry of the drug by tweaking the composition of the drug (Joseph, 2003).  Another 
unhealthy trend observed in the international platform is that pharmaceutical MNEs take over 
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local pharmaceutical companies in developing countries at a very high price (Joseph, 2003). 
Sometimes, in order to recover payments made for acquisition, MNEs concentrate on 
manufacturing and marketing of costly branded products and use the marketing and 
distribution networks of the acquired company to push their expensive patented and branded 
medicines, thereby displacing generic products from the market (Chandler, 1959). 
Introducing branded products without displacing non-branded drugs transparently can 
improve stakeholder perceptions of MNEs (Rai, 2008). 
Need	Based	CSR	
The use of a subsidiary in a foreign country for identification of an appropriate initiative can 
the improve market position of the MNE (Dunning, 1999).  The nature of the global 
pharmaceutical industry encourages MNEs to concentrate / focus on the 8th MDG that 
requires participation of global partnerships for providing access to medicines.  To regulate 
the supply of medicines by drug manufacturers from developed countries, the WHO 
promotes Ethical Criteria for Medical Drug Promotion to encourage the rational use of drugs 
by everyone across the globe.  WHO reports indicate that 85% of the global pharmaceutical 
companies that dominate the drug market are based in the USA, UK or Japan.  The figures 
reported by WHO also highlight that the marketing spends of these companies is one-third of 
their total sales revenue and twice the budget allocated by them to research and development 
(R&D) related activities. The marketing initiatives of MNEs are focused on drugs meant for 
the mass market, due to anticipated high returns in terms of sales revenue. R&D investments 
are motivated by the paying capacity of purchasers, thereby ignoring the needs of patients 
whose paying capacity is low.  These practices reflect the conflict of interest of the drug 
manufacturers’ approach towards the needs of stakeholders in a foreign market.  Annual 
reports of top drug supplier MNEs were reviewed to understand their social responsibility 
driven initiatives and their focus on marketing objectives (Table 1).  As shown in Table 1, 
investments of the 9 companies reviewed towards CSR initiatives do not address the issues of 
the local area i.e. providing financial aid to patients with low or no paying capability and 
building of infrastructure that will allow higher trade and availability, therefore, lead to local 
development. Identification of CSR initiatives based on the need of the local market can 
improve ability of stakeholders to differentiate between brands and be loyal to a brand that is 
satisfies their needs. 
Distribution	for	Penetration	
An anticipated increase in future consumption of medicines and conditions of markets in 
countries with high business potential for sales of drugs both require pharmaceutical MNEs 
to understand causes and patterns in developing countries (Sundaram, 2014).  In-depth 
knowledge with a business strategy can help a company to penetrate a foreign market 
(Dunning, 1999).  The current market in developing countries is generally made up of a large 
number of suppliers and retailers (Buckley and Ghauri, 2004) and at every exchange between 
these actors there is a mark-up applied to prices (Ghauri and Usunier, 2003).  As a result, 
manufacturers compete with each other through salesmen and retailers by manipulating the 
supply chain and stocks available in the marketplace (Gupta et al., 2008).  Drugs 
recommended by suppliers are based on profitability from each sale, and retailer 
recommendations are driven by their relationships with the manufacturer (Sundaram, 2014).   
As shown in Figure 2, the acquired company supports an MNE to spread its network using 
such linkages as its subsidiary. MNEs use their brand to promote products through a network 
of distributors, medicine retailers and hospitals that provide deep access into the remote 
markets (Gupta et al., 2010).  Pharmaceutical MNEs promote branded medicines also by 
engaging medical practitioners through their local linkages (Grace, 2004).  Staff at the health 
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centres or hospitals, doctors or pharmacists act as representatives of MNEs in their local 
market and provide assurance about the quality of raw materials used and processes adopted 
by MNEs during production using marketing techniques like relationship marketing and 
brand knowledge (Gupta et al., 2008).  Engagement of actors in the distribution network with 
MNEs results in development of their technical and sales skills (Gupta et al., 2008).  Training 
provided by MNEs to these individuals indirectly enables them to qualify for superior jobs 
and improve their life-style and social status. Such initiatives taken up by brands build a 
positive reputation and improve recognition of the value offered by the brand in its target 
segment (Gupta et al., 2010).   
The distribution network of MNEs provides resources required by an MNE and its subsidiary 
to develop its credibility and to establish the legitimacy of its actions in the developing 
country (Buckley and Ghauri, 2004).  The centralization of procurement and decentralization 
of distribution of medicines by states has improved the situation relating to access to 
medicines in India.  Centralized procurement of drugs in such cases has also led to reduction 
in prices of drugs due to the volumes being purchased, thereby encouraging independent 
retailers of medicines to promote low cost generic medicines (Grace, 2004).  The centralized 
procurement and decentralized system of distribution of medicines adopted by these states in 
India have received criticisms from MNEs because these activities are performed through 
agencies appointed by state government using a bidding system. Bidding allows state 
governments to assess the technical and financial capabilities of the suppliers (Chaudhry et 
al., 2005).  Most often MNEs score highly on the technical parameter identified but owing to 
their marketing spend, they fail to compete at the price point, thereby, losing the business 
(Chaudhry et al., 2005).  Hence, appointing independent self-employed pharmacists or 
medicine shops outside hospitals as members of distribution network and incentivizing the 
superior performers can provide access to medicines for consumers and benefit the MNE 
with superior recognition and higher profits (Lee, 2012).  Use of a brand for adoption of this 
model becomes important to create recognition for rewards and incentives to members of 
distribution networks. 
Public-private	partnership	
Access to medicine as defines by WHO is dependent on four pillars, namely 1) Rational Use, 
2) Affordable Prices, 3) Sustainable Financing, and 4) Reliable Supply System (Schustereder 
and Jütting, 2008).  While rational use of medicines and sustainable financing are considered 
to be the responsibility of government, MNEs can aim to improve availability of medicines at 
affordable prices with a reliable supply system while taking care of their profit margins, and 
gain an increase in their market penetration while diversifying their product lines etc. (Allred 
and Park, 2007).  A study conducted by Ozgediz and Riviello (2008) explains that a lack of 
infrastructure in rural areas of developing markets makes thr supply of essential drugs 
difficult for public-partnerships.  Healthcare infrastructure in rural areas of developing 
countries built by local governments can create an opportunity to provide healthcare in 
remote areas.  Maintaining a stock of essential medicines through government managed 
public health facilities and supplies made at minimal cost from pharmaceutical firms will 
facilitate public private partnerships for the provision of instant medication and generic 
medication to the poor (Ozgediz and Riviello, 2008).  The government of Tamil Nadu in 
India has been able to successfully build an efficient health and supply system by facilitating 
public-private partnership to provide access to medicines.  The success of the government of 
Tamil Nadu is based upon cooperation between political leaders, industry and administrative 
services and has been able to attract public support required for reformation. The 
aforementioned cooperation was driven by managerial skills and management frameworks 
and resulted in identification and deployment of resources required to improve the network of 
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health facilities in Tamil Nadu.  The success story of Tamil Nadu in India was reviewed by 
Muraleedharan et al. (2009), who explained how adoption of government run health care 
institutions by industrialists, making philanthropic contributions via maintenance and upkeep 
of hospitals and health care centres, can improve access to medicines 
Market	Based	Pricing		
FDI in the pharmaceutical sector should result in lowering of drug prices through 
improvement in supply and increase in sales of drugs (Ghauri and Usunier, 2003). But 
expenses incurred by MNEs in the creation and promotion of their brand to create 
recognition, apart from costs of supplying medicines across national boundaries, push 
managers of MNEs to charge a premium for their drugs. To provide access to medicine for 
everyone, WHO recommends the creation of a list of certain important medicines as essential 
drugs and making patients aware of a price at which these should be sold, so that poor 
consumers do not have to spend exorbitantly?  Governments in developing countries also 
attempt to address such issues through sustainable financing in the form of a fund as a 
percentage of its GDP or by publishing a list of essential medicines.  Therefore, essential 
medicines when sold under a price cap in developing countries are not considered as 
profitable by MNEs (Pederson, 2011). The inability of pricing policies of MNEs and price 
controls levied by national institutions or governments in developing countries to ensure 
access to essential medicines for the poor was highlighted by Scherer and Watal (2002).  
Pricing practices of 150 Norwegian multinationals were investigated by Pederson (2011), by 
reviewing the current literature on transfer pricing and by conducting a survey of 150 transfer 
pricing advisory consultants in Nigeria. The findings of Pederson (2011) explain that the 
current academic understanding of transfer pricing reflects on its use for strategic 
optimization of management control and taxation in the host country, indicating that tax 
legislation of the host country plays an important role in pricing for MNEs.  Hussein and 
Kachwamba (2011) studied the combined influence of globalization, purchasing power of the 
buyer, inadequate institutional participation, information asymmetry and unstructured 
distribution networks on product quality.  As noticed by Hussein and Kachwamba (2011), 
unfair competition in developing markets due to inadequate institutions and uncoordinated 
distribution result in unethical practices which work as a catalyst for MNEs to increase the 
prices of their products and makes price conscious consumers trade product quality and 
product performance for cheaper prices. Hence, market based pricing was suggested as a 
strategy to be adopted by MNEs for improving their performance in developing countries. 
Reciprocity	
The task force monitoring the progress of MDGs highlighted official development assistance, 
market access and debt sustainability as important indicators useful for evaluating 
engagement of MNEs in the achievement of the 8th target. They recommended cancellation of 
bilateral debts and inclusion of tariff and quota free access for providing access to medicines 
for all the patients.  Research studies conducted by scholars such as Gugler and Shi (2009), 
from an international marketing point of view, report that the success of MNEs in developing 
markets depends upon their engagement in addressing social issues prevailing in the target 
market.  Social engagement strategies created by MNEs are constrained by moral obligations 
imposed by the stakeholder community.  International trade literature like Wade (2003) 
reflects on the role played by agreements such as TRIPS (Trade-Related Aspects of 
Intellectual Property Rights) that are monitored by organisations like the World Trade 
Organisation (WTO) regarding MNE engagement in developmental activities in developing 
countries. Wade (2003) examined how international regulations restrict the development 
policy options available to MNEs and the restrictions they impose on local governments in 
developing countries.  This study discusses how two of three main agreements, i.e. TRIMS 
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on investment measures and GATS on trade in services, limit the authority of local 
government in constraining the choices available to MNEs in developing countries.  The third 
agreement TRIPS further pushes local governments to protect property rights of MNEs from 
infringement by local firms. These three agreements as explained by Wade (2003) demotivate 
governments in developing countries from focusing on development of their local industries 
and push them to support MNEs from developed countries in generating wealth by 
penetrating their markets. Wade (2003) explains how these three agreements are removing 
the possible opportunities of superior performance provided by globalization for local firms 
in developing countries, therefore, they are bad for the development of developing countries.  
The author puts emphasis upon integrating a social agenda for development of developing 
markets with a commercial agenda of MNEs to drive the performance of a firm. 
The benefits of acquisition, branding and distribution as a market entry strategy for control, 
marketing and penetration by pharmaceutical MNEs have been recognized in the academic 
literature (Meyer, 2004) but returns on these initiatives for the MNEs have not been 
recognized by the marketing scholars up to now.  Few scholars such as Venkatraman and 
Ramanujam, (1986) have tried to develop scales for evaluating the efficiency of firms or the 
organisational effectiveness as business performance.  As these studies have been conducted 
in different settings, indicators of performance used by these researchers are different in each 
case. Ten different approaches were reviewed by Venkatraman and Ramanujam (1986) using 
two dimensional classification schemes, i.e. a financial versus operational scheme and 
primary versus secondary data based scheme, to understand the measurement of business 
performance.  Selection of these two basic but different dimensions was considered to be 
important for measuring business performance by Venkatraman and Ramanujam (1986). 
Bassioni et al. (2005) also attempted to construct a conceptual framework for measuring 
business performance of firms operating in the construction industry using balance scorecard 
and business excellence models, by means of case studies and expert interviews.  Marr and 
Schiuma (2003) made an attempt to explore business performance models developed by 
difference academic researchers working in the field of accounting, human resources, 
operations and marketing. A citation analysis conducted by Marr and Schiuma (2003) 
reflected upon the appropriateness of balance scorecard model for measuring performance.  
The performance of 156 food franchisors operating in the Korean franchising industry were 
studied by Lee et al. (2015) through examination of relationships between top management 
factors, franchisor market orientation and competitive strategy.  The findings of Lee et al. 
(2015) reveal that top management factors such as management emphasis and risk aversion 
can lead to market orientation, which will influence differentiation and costs to improve 
business performance.  Recommendations made by Austin and Seitanidi (2012) propose that 
organisational orientation to the target market in a developing country towards inclusive 
practices in business relationships can lead to poverty reduction. 
RETURNS ON INVESTMENTS FOR DEVELOPMENTS BY MNEs 
The superior performance of MNEs when understood from a marketing perspective explains 
the returns received by MNEs from internationalisation as direct or indirect returns (Aaker, 
1996). Isobe et al. (2000) reviewed the performance of investments made by MNEs into joint 
ventures to understand their market entry strategy, resource commitment and level of 
technology transfer.  The findings of Isobe et al. (2000) reflected on various direct and 
indirect returns received by an MNE from its entry strategy, such as perceived economic 
performance, local control and availability of resources in the target market.  Other studies 
such as Austin and Seitanidi, (2012) explored the benefits of superior performance for an 
MNE from an industrial perspective and discussed stakeholder value or competitiveness as 
direct returns. Scholars like Valentine (2011) proposed the use of technology for increasing 
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the mix of direct and indirect benefits such as market share, differentiation and 
competitiveness for MNEs.  However, from a return on investments point of view, these 
benefits should be studied separately. 
 
Indirect Returns for MNEs 
A study conducted by Rugman (1980) used the general theory of direct investments to denote 
different activities like production or sales related activities of MNEs as individual benefits 
provided by each target market.  The findings of Rugman (1980) reflect upon the overall 
structure and operational benefits provided to MNEs for building their competitiveness 
through brand identity and brand equity for shareholder value. Prahlad (1994) recognized the 
need for a shift in focus of MNEs competing in international markets from shareholder value 
to stakeholder value. Creation of stakeholder value as explained by Prahlad (1994) depends 
upon four areas in which MNEs compete with each other. Those four areas identified by 
Prahlad (1994) are 1) markets with potential for investments, 2) markets with consumers with 
purchasing ability, 3) markets that provide skilled labour required to perform business and 4) 
markets that provide a network of sellers to facilitate penetration with or without the help of 
technology. Using stakeholder views of MNE performance in these areas and considering 
intellectual capital as a resource used by MNEs in developing countries, Riahi-Belkaoui 
(2003) tried to understand the benefit of control exercised by an MNE on its assets.  He noted 
that stakeholder value in line with a resource-based view of a firm when used to control brand 
management indirectly improves competitiveness of the brand in the target market.  Meyer 
(2004) noticed that individual firms in host countries become the initial catalyst for 
enhancing the understanding of MNEs about stakeholder value by leading the interaction 
between MNEs and the local environment.  Austin and Seitanidi (2012) reviewed literature 
on corporate social responsibility and collaborative value creation to explain how value 
created for the stakeholder increases with every increase in performance as a direct benefit.  
Global brand equity of MNEs was studied from the stakeholder viewpoint by Torres et al. 
(2012) using panel data ranging from year 2002 till 2008 of 57 global brands from 10 
countries. They aimed to understand the brand policies for satisfying community interests 
through reinforcement of credibility of the socially responsible nature of the brand among its 
stakeholders.  The findings of the research conducted by Torres et al. (2012) explain why 
managers seeking returns from global branding management practices should combine their 
global marketing strategies formulated to create brand value with the needs and interests of 
the local community as CSR initiatives adopted for different stakeholders.  As explained by 
Torres et al. (2012), different initiatives when designed individually for different 
communities can have a positive influence on global brand equity of the MNE.  Atilgan et al. 
(2009) focused upon different dimensions and measurements of global brand equity to 
understand the differences between economically and culturally different markets.  Using a 
brand equity model, Atilgan et al. (2009) explained why brand trust is becoming a more 
important construct for international penetration in comparison to brand awareness, and 
revealed that global brand equity can be directly measured on four dimensions, i.e. 1) 
perceived quality 2) brand loyalty 3) brand association and 4) brand trust.  
A review of brand performance and market share of multi-national and local brands in 
transition economies was performed using a resource-based view by Gao et al. (2006) to 
understand the impact of brand competitiveness, market environment and duration of 
existence of a brand in the market.  Arguments made by Gao et al. (2006) about sustainable 
competitive advantage of a brand are based on the availability of valuable, rare and non- 
reproducible resources available to a brand in a competitive market.  As explained by this 
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research, the strength of MNEs is based on the use of management philosophies to develop 
competitiveness in comparison to the use of local infrastructure, local information, local 
support and local resources by local brands.  Drawing upon the analysis of responses received 
from senior executive of 408 brands operating in 52 product categories in the Chinese 
market, Gao et al. (2006) have explained why brand level factors indirectly influence 
performance and competitiveness of a brand in a market. In line with findings of other studies 
like Porter and Kramer (2002), Gao et al. (2006) explained that brands with stronger local 
advantages in the form of market knowledge and local resources will be more competitive 
and will be able to gain a higher share of the market.  The competitive advantage based on 
strategic philanthropy has been explained as a vague or tenuous connection between the 
contributions made by the company to a social cause and the business performed by the 
company (Porter and Kramer, 2002).	 	 This study recommends integration of social and economic 
objectives to build brand competitiveness in international markets. 
 
Direct Returns for MNEs	
Fahy and Smithee (1999) identified credibility of a brand as an invisible asset useful for 
building core competencies needed to survive in a competitive market. Another study 
conducted by Sweeney and Swait (2008) investigated the role of brand in managing retention 
of customers in relational services in a retail setting and proposed that credibility of the brand 
underlies the role played by a brand in retaining customers in a competitive market through 
relationships, satisfaction and service quality.  The findings of Sweeney and Swait (2008) 
indicate that brand credibility defends the actions of the brand by increasing its word of 
mouth publicity and customer retention.  The argument presented by Sweeney and Swait 
(2008) is based on the assumption that the link between role of brand and customer retention 
is mediated by customer satisfaction and commitment.  Considering these concepts for MNEs 
attempting to provide access to medicines to people in remote rural areas with high price 
sensitivity, a study conducted by Erdem et al. (2002) was useful. Erdem et al. (2002) 
reviewed both tangible and intangible attributes to understand if consumer price sensitivity is 
in any way linked with brand credibility, i.e. will the impact of product price on consumer 
utility be moderated by brand credibility?  The findings of research conducted by Erdem et al. 
(2012) indicate that brand credibility decreases price sensitivity.  However, these results of 
Erdem et al. (2002) also explain that the magnitude of a brand credibility’s link with 
consumer choice and price sensitivity varies across product categories. Cost-based strategies 
of MNEs were analysed by Aulakh et al. (2000) to understand their performance and to 
highlight the returns they received from exports of branded products to developing markets.  
As explained by Aulakh et al. (2000), awareness of the performance of brand informs 
consumers about brand differentiation and enables MNEs to clarify confusions in their minds 
related to the brand.  Authors such as Laurent et al. (1995) recognized aided, spontaneous and 
top of the mind as measures of brand awareness and explained that superior performance of 
MNEs in a developing market provides a direct return in the form of brand credibility.  
Performance of a brand reflects on its capabilities and enables its audience to differentiate 
between competing brands. Using data on 269 subsidiaries of MNEs in 27 countries, Surroca 
et al. (2013) explained that MNEs’ responses to the expectations of stakeholders require 
Indirect returns for MNEs are Stakeholder Value, Brand Equity and 
Brand Competitiveness 
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managerial attention towards corporate social responsibility and socially responsible 
behaviour of firms.  Surroca et al. (2013) applied institutional theory to propose that the 
building of stakeholder value in the host country increases pressure on the home office 
wherein managers in the corporate office have very little knowledge about challenges faced 
by stakeholders in the host country.  Such a situation pushes managers in corporate settings to 
seek support from linkages created with or without a subsidiary to make recommendations 
for investments in social development or to resolve social issues being faced by customers in 
the target country. Decisions in such cases are made on behalf of the brand or the MNE by 
either its subsidiary or local linkages and responsible actions taken by a brand build its 
reputation in an international market and make pushing the products down the supply chain 
easy for brand managers.  From the point of view of access to medicines, and MNE’s 
performance indicates its capability to improve stakeholder value, its market share and 
competitiveness of the brand to provide access to medicines.  Simultaneously, 
acknowledgement of superior performance of a brand in a developing market in terms of 
access to medicines will spread awareness about its credibility, and enable patients to 
differentiate between generic, branded generic and branded medicines.  Recognition of these 
features of a pharmaceutical brand will create a reputation of being socially responsible for	
the brand of the MNE.	
	
RECOMMENDATIONS 
Focus on building a corporate brand to demonstrate the company’s innate character as it 
provides distinct returns such as protection from competitors, and enables brand managers to 
create and communicate credibility of their organizational actions across borders without 
focusing on the product related activities.  Particularly for MNEs that invest in developing 
markets for opportunities of growth, satisfying the social needs of the target market becomes 
very important.  These requirements of developing markets require participation of the 
private sector in resolving their social issues.  Hence, it is important for brand managers to 
progress from creation of a corporate brand to creation of a brand identity so that the 
investments made in the fulfilment of social responsibilities imposed by developing countries 
can be communicated as mission, vision and values of the brand.    
Integrate poverty reduction into the corporate agenda: When poverty reduction becomes an 
agenda of the top management, managers are encouraged to integrate it as an organisational 
goal into every business activity performed by staff performing different functions in 
different departments.   
Use technology to engage stakeholders in value creation: Technology has empowered 
organisations to collect and benefit from information about stakeholders. Simultaneously, 
technological advancements have also enabled stakeholders to raise their concerns related to 
actions taken by companies.  Therefore, engaging stakeholders to identify opportunities of 
value creation becomes easy with the help of technology. 
Incorporate capability enhancement into industrial practices:  Use of industrial networks 
for distribution of branded products requires ensuring rational benefits for each member in 
the supply chain.   
Direct	returns	for	MNEs	are	Brand Credibility, Brand Differentiation 
and Brand Reputation 
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Engage distribution network into CSR initiatives: Members of the supply network of MNE 
brands are generally small and medium sized firms or micro level entrepreneurs or 
individuals as retailers who understand the needs of the market they cater to.  Hence, 
engaging such alliance firms in foreign countries into business strategy and using their 
infrastructure to adopt strategies developed and improve performance can have both direct 
and indirect returns for channel partners of an industrial distribution network. 
Use research techniques to identify CSR investments: Although CSR has become an 
important agenda for all businesses, decisions of CSR investments are not informed decisions 
because there is no information available that could assist to develop strategies that will 
satisfy need based CSR.  Therefore, use of research techniques will enable MNEs to identify 
their CSR investments. 
Production innovation for the host country:  Stakeholder observations about the use of 
developing markets as testing grounds of new medicines being developed, simultaneously 
pushing these innovative drugs into countries where the purchasing capability of customers is 
very high raises concerns about the use of innovation only for production purposes. 
 
Conclusion 
The flow of FDI by MNEs to developing countries with changes in ownership and expansion 
of businesses raises concerns that such takeovers could lead to ‘an oligopolistic market’ 
where a few companies might end up deciding the prices of essential medicines, adversely 
impacting the interest of public health.  A contrary view refers to the growth of the industry 
in the host country due to the entry of MNEs.  In 2010, the OECD reported benefits and costs 
related to FDIs linked with the development of developing countries.  A large share of FDI 
flows in recent years towards developing countries using different routes.  Simultaneously, 
the challenges posed by business environment, industrial dynamics and governance issues 
like corruption and red-tape-ism in countries like India, China or Africa push MNEs to hold 
back their controls in the home office and use brands to position themselves appropriately in 
a foreign market.  Brand based communications require synchronization of every activity 
related to the MNE or its products with the company’s mission, vision and values apart from 
ensuring stakeholder engagement and value creation.    
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